Amylyx Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Amylyx Pharmaceuticals Inc cash flow-to-debt ratio. Amylyx Pharmaceuticals Inc (AMLX) has a Cash Flow-to-Debt Ratio of -1.24x as of June 2026, meaning its operating cash flow of $-31.42 Million could theoretically repay -1% of its total liabilities ($25.40 Million) in one year. Check earnings quality score of Amylyx Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Amylyx Pharmaceuticals Inc (2019–2025)
Cash flow-to-debt ratio of Amylyx Pharmaceuticals Inc from 2019 to 2025. Historical debt coverage capacity for Amylyx Pharmaceuticals Inc across 7 annual periods. Check Amylyx Pharmaceuticals Inc (AMLX) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Amylyx Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Amylyx Pharmaceuticals Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Amylyx Pharmaceuticals Inc. For the full cash flow conversion analysis, see how efficiently does Amylyx Pharmaceuticals Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.50x | $-123.34 Million | $27.39 Million | ▲ +22.4% |
| 2024 | -5.81x | $-167.65 Million | $28.87 Million | ▼ -4193.7% |
| 2023 | 0.14x | $11.92 Million | $84.02 Million | ▲ +104.0% |
| 2022 | -3.54x | $-179.87 Million | $50.85 Million | ▼ -1114.4% |
| 2021 | -0.29x | $-74.80 Million | $256.78 Million | ▲ +35.8% |
| 2020 | -0.45x | $-36.70 Million | $80.83 Million | ▼ -21.4% |
| 2019 | -0.37x | $-10.69 Million | $28.58 Million | — |